
REPL Stock Forecast & Price Target
REPL Analyst Ratings
Bulls say
Replimune Group Inc has increased its probability of approval for its RP1 + Opdivo treatment in anti-PD1 failed melanoma patients to 85%, indicating strong confidence in its clinical outcomes. The favorable safety profile of RP1 + Opdivo, with only 12.8% of patients experiencing G3+ treatment-related adverse events, further supports its potential for regulatory approval. Given the promising trial results, Replimune is positioned well in the market, with performance metrics indicative of a strong future for its oncolytic immunotherapies pipeline.
Bears say
Replimune Group Inc faces several significant risks that contribute to a negative outlook on its stock, particularly surrounding its product candidate RP1, which is currently under scrutiny by the FDA due to concerns regarding the adequacy of clinical trial data and the effectiveness of the trial design. The company may struggle to generate compelling efficacy and safety data, and any failure to meet regulatory requirements for marketing authorization could impede its progress and threaten long-term viability. Additionally, the potential for medium- to long-term dilution presents further financial risks, as does the uncertainty regarding the early-stage pipeline of oncolytic virus candidates.
This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.
REPL Analyst Forecast & Price Prediction
Start investing in REPL
Order type
Buy in
Order amount
Est. shares
0 shares